Safety
AEs were reported in 90% (n=19/21) of patients with CVID after the first and second doses. The most common event was local pain at the injection site (20/21), followed by fatigue (10/21), headache (7/21), fever (5/21), myalgia (3/21), and arthralgia (2/21) after the first dose. A similar AE spectrum was observed after the second dose. AE incidence is summarized in Fig 4. AE mean durations after the first and second doses were 3.55 (±2.19 SD) and 2.95 (±2.04) days, respectively. PGA-VAS-100 was 18.25 (±21.96) and 16.75 (±22.38) points. We also evaluated a broad spectrum of laboratory parameters, including biochemical, hematological, immunological, and inflammatory parameters. We detected significantly increased soluble CD25 levels after both vaccine doses. No changes in the total blood count, liver or renal function, and coagulation were observed, and no autoantibodies were detected during the follow-up period. Vaccination did not increase inflammatory markers, except for soluble IL-2R (sCD25) levels, which were significantly increased after both vaccine doses. A complete overview of these parameters is provided in Supplementary Table 1.